Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P26378
UPID:
ELAV4_HUMAN
Alternative names:
Hu-antigen D; Paraneoplastic encephalomyelitis antigen HuD
Alternative UPACC:
P26378; B1APY6; B1APY7; B1APY8; B7Z4G7; Q8IYD4; Q96J74; Q96J75; Q9UD24
Background:
ELAV-like protein 4, also known as Hu-antigen D and Paraneoplastic encephalomyelitis antigen HuD, plays a pivotal role in the post-transcriptional regulation of mRNAs. It binds to AU-rich elements in the 3' UTR of target mRNAs, influencing mRNA stability, alternative splicing, and translation. This protein is crucial for neuron-specific RNA processing, contributing to nervous system development, learning, memory, and neuronal differentiation.
Therapeutic significance:
Understanding the role of ELAV-like protein 4 could open doors to potential therapeutic strategies. Its involvement in mRNA stabilization and protection from decay, especially in neuronal development and function, highlights its potential as a target in neurodegenerative diseases and cognitive disorders.